PD1 / PDCD1 / CD279 Neutralizing Antibody

1/1
Price:
Size:
Number:

PD1 / PDCD1 / CD279 Neutralizing Antibody ( antibody) General Information

Product name
PD1 / PDCD1 / CD279 Neutralizing Antibody
Validated applications
Neutralization
Species reactivity
Reacts with: Human
Specificity
Human PD-1
Has cross-reactivity with Rhesus PDCD1 (Catalog # 90305-K08H) in ELISA assay
No cross-reactivity with mouse PDCD1 Protein (Catalog # 50124-M08H) and rat PDCD1 (Catalog # 80448-R08H) in ELISA assay
Immunogen
Recombinant Human PD1 / PDCD1 / CD279 Protein (Catalog#10377-H08H)
Preparation
This antibody was a humanized antibody obtained from a mouse immunized with the recombinant Human PD1 / PDCD1 Protein (Catalog#10377-H08H; NP_005009.2; Met 1-Gln 167) and was produced using recombinant antibody technology.
Source
Human IgG4 Clone #HF06
Purification
Protein A
Formulation
0.2 μm filtered solution in Histidine and Arginine buffer containing 120mM NaCl, 0.02% Tween 80, pH6.0
Conjugate
Unconjugated
Endotoxin
< 3 EU/mg
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

PD1 / PDCD1 / CD279 Neutralizing Antibody ( antibody) Validated Applications

Notes
Block: In a functional ELISA which immobilized recombinant Human PD1-L1 protein (Catalog # 10084-H08H) at 10 μg/mL (100 µL/well) in the plate, the Human PD1 Monoclonal Antibody (Catalog # 10377-H08H) can block the binding of 1 μg/mL of recombinant Human PD1/Fc Chimera (Catalog # 10377-H03H) to human PD1-L1 , the EC50 is 1.31 μg/mL.
Neutralization: The neutralization activity of PD1 Neutralizing Antibody is Measured by its ability to neutralize PD1_PD-L1 pathway mediated inhibition of IFN-gamma secretion in the Mixed lymphocyte Reaction.
Please Note: Optimal concentrations/dilutions should be determined by the end user.

PD1 / PDCD1 / CD279 Neutralizing Antibody ( antibody) Images

Effect of Human PD1 HF06 antibody on IFN-gamma production in the Mixed Lymphocyte Reaction (MLR). Purified CD4T cells were cultured with allogeneic dendritic cell, as prepared by culturing monocytes in GM-CSF and IL-4 medium for seven days, in the medium containing serial concentrations of human PD1 HF06 antibody (Catalog 10377-HF06). Six days later, the IFNg secretion in the medium was measured using IFN-gamma Quantitative ELISA Kit.

PD1 / PDCD1 / CD279 Neutralizing Antibody: Alternative Names

Anti-CD279 Antibody; Anti-hPD-1 Antibody; Anti-hPD-l Antibody; Anti-hSLE1 Antibody; Anti-PD-1 Antibody; Anti-PD1 Antibody; Anti-SLEB2 Antibody

PD-1 Background Information

Programmed cell death 1, also known as PDCD1, is a type I transmembrane glycoprotein, and is an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-1 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. PD1 has been suggested to be involved in lymphocyte clonal selection and peripheral tolerance, and thus contributes to the prevention of autoimmune diseases. Furthermore, PD1 is shown to be a regulator of virus-specific CD8+ T cell survival in HIV infection. As a cell surface molecule, PDCD1 regulates the adaptive immune response. Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function.
Full Name
programmed cell death 1
References
  • James ES, et al. (2005) PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. 6(5): 430-7.
  • Okazaki T, et al. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 19(7): 813-24.
  • del Rio ML, et al. (2008) PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int. 21(11): 1015-28.
  • Riley JL.(2009) PD-1 signaling in primary T cells. Immunol Rev. 229(1): 114-25.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait